No Data
No Data
Sector Update: Health Care Stocks Edge Higher Pre-Bell Friday
Sagimet Biosciences' MASH Drug Meets Main, Secondary Goals in Phase 2b Study
Express News | Sagimet Biosciences Inc - Denifanstat Shows Significant Improvements in Mash Resolution and Fibrosis
Sagimet Biosciences Announces Publication of Results From Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 MASH in The Lancet Gastroenterology & Hepatology
Express News | Sagimet Biosciences Announces Publication of Results From Phase 2B Fascinate-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 Mash in the Lancet Gastroenterology & Hepatology
Sagimet Biosciences' Denifanstat Receives Buy Rating on FDA's BTD and Promising Trial Results
No Data
No Data